Curriculum Vitae

Ronald Wayne Orso, MD
Alabama Clinical Therapeutics, LLC
52 Medical Park East Drive, Suite 203
Birmingham, Alabama 35235

Telephone: (205) 833-2228
Fax: (205) 833-6225

Additional Offices:

Alabama Clinical Therapeutics, LLC
Birmingham Obstetrics and Gynecology, PC
800 St. Vincent's Drive, Suite 500
Birmingham, AL 35205

Alabama Clinical Therapeutics, LLC
Birmingham Pediatric Associates
806 St. Vincent's Drive, Suite 615
Birmingham, AL 35205

Education:

1972-1975	OB-GYN, Internship and Residency Lloyd Noland Hospital Birmingham, AL
1972	Doctor of Medicine University of Alabama School of Medicine Tuscaloosa, AL
1968	Bachelor of Science University of Alabama Tuscaloosa, AL

Work Experience:

02/2016-Present	Investigator Alabama Clinical Therapeutics Birmingham, Alabama
1975 -Present	Private Practice Birmingham Obstetrics and Gynecology, PC Birmingham, AL

Certifications and Licenses:

State of Alabama #6333
American Board of Obstetrics and Gynecology

Affiliations:

American Medical Association
Birmingham Surgical Society
Birmingham Academy of Medicine
Birmingham OB-GYN Society
American Fertility Society
Member, American Medical Association
Member, Medical Association, State of Alabama
Representative to Alabama Health Council
Past Member of the University of Alabama School of Medicine Dean's Advisory Council
Adjunct Instructor, University of Alabama School of Nursing

Awards:

University of Alabama School of Medicine Alumni Association-
2015 Hettie Terry Community Service Award
American Medical Association Physician Recognition Award 2002

Publications:

Hormone Replacement Therapy, Information Quarterly, Spring 1993, Volume 2, No. 2

Health and Today's Woman, series of six articles, Suburban South, 1995

The Role of Expanded Cholesterol Testing, The Female Patient, OB/GYN Edition
Volume 28, No. 10, October 2003

Research Experience:

A Phase 3 Study to Evaluate the Efficacy and Safety of XXX in Combination with XXX for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women

A Phase 3 Study to Evaluate the Safety and Efficacy of XXX in Combination with XXX in Subjects with Moderate to Severe Endometriosis-Associated Pain

Extension Study to Evaluate the Efficacy and Safety of XXX in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids

A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral XXX Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis

Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging, Phase 2b Study to Investigate the Efficacy of XXX in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)

Solubilized XXX and/or XXX Intra-Vaginal Efficacy and Safety (SMART GIVES)

Research Experience (continued):

A Multicenter, Randomized, Double-Blind Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of XXX and XXX in the Treatment of Bacterial Vaginosis

A Phase 3b Study to Evaluate the Long-Term Safety and Efficacy of XXX in Combination with XXX for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women

A Phase 3 Study to Evaluate the Safety and Efficacy of XXX in Combination with XXX in Subjects with Moderate to Severe Endometriosis-Associated Pain

Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center
Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of XXX in Healthy Seronegative Women, 16 to 35 Years of Age

Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of XXX in Women with Polycystic Ovary Syndrome

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Single-arm Open-label Treatment Period, to Assess the Efficacy and Safety of XXX in Women Suffering from Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Clinical Study to Investigate the Long-Term Safety of XXX in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated with Menopause

A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of XXX for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women

A Phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of XXX in subjects with moderate to severe endometriosis-associated pain

Biospecimen Collection Protocol: Infectious Disease & Healthy Donors

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of XXX to XXX in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

XXX in Combination with Combined Oral Contraceptives in Women with Moderate to Severe Endometriosis Pain

A phase 3, double-blind, multicenter, randomized, placebo-controlled study to assess the efficacy and safety of XXX Gel, 1% for the treatment of bacterial vaginosis

Prospective Collection of Samples for Research

A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the XXX (MK-8415) Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger

Research Experience (continued):

A double-blind randomized extension study to assess the long-term efficacy and safety of XXX in subjects with endometriosis-associated pain.

Ronald Wayne Orso

Ronald Wayne Orso, MD

3/29/2021

Date

Updated March 2021